Reblozyl (luspatercept-aamt) - BMS, Merck (MSD)
A Clinical Study on the Efficacy and Safety of Luspatercept Monotherapy for Cancer-Related Anemia (Single-Arm, Multicenter) (ChiCTR) - Oct 16, 2026 - P=N/A | N=42 | Not yet recruiting | Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital 
New trial • Anemia • Breast Cancer • Colorectal Cancer • Gastric Cancer • Hematological Malignancies • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor
https://www.chictr.org.cn/showproj.html?proj=343208
 
Oct 16, 2026
 
Prev Next